124 related articles for article (PubMed ID: 36576661)
1. FAT4 activation inhibits epithelial-mesenchymal transition (EMT) by promoting autophagy in H2228/Cer cells.
Yang Y; Li Y; Yang Q; Liu Z; Chang X; Yang H; Liu J; Li Z; Zuo D
Med Oncol; 2022 Dec; 40(1):64. PubMed ID: 36576661
[TBL] [Abstract][Full Text] [Related]
2. ZYY-B-2, a novel ALK inhibitor, overcomes resistance to ceritinib by inhibiting P-gp function and induces apoptosis through mitochondrial pathway in ceritinib-resistant H2228 cells.
Gao Y; Liu T; Liu J; Yang Y; Sun K; Li Z; Zhai X; Zuo D
Chem Biol Interact; 2023 Jul; 379():110516. PubMed ID: 37116853
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic ALK regulates EMT in non-small cell lung carcinoma through repression of the epithelial splicing regulatory protein 1.
Voena C; Varesio LM; Zhang L; Menotti M; Poggio T; Panizza E; Wang Q; Minero VG; Fagoonee S; Compagno M; Altruda F; Monti S; Chiarle R
Oncotarget; 2016 May; 7(22):33316-30. PubMed ID: 27119231
[TBL] [Abstract][Full Text] [Related]
4. FAT4 regulates the EMT and autophagy in colorectal cancer cells in part via the PI3K-AKT signaling axis.
Wei R; Xiao Y; Song Y; Yuan H; Luo J; Xu W
J Exp Clin Cancer Res; 2019 Mar; 38(1):112. PubMed ID: 30832706
[TBL] [Abstract][Full Text] [Related]
5. FAT4 silencing promotes epithelial-to-mesenchymal transition and invasion via regulation of YAP and β-catenin activity in ovarian cancer.
Malgundkar SH; Burney I; Al Moundhri M; Al Kalbani M; Lakhtakia R; Okamoto A; Tamimi Y
BMC Cancer; 2020 May; 20(1):374. PubMed ID: 32366234
[TBL] [Abstract][Full Text] [Related]
6. Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial-mesenchymal transition is critical in conquering ALK-positive lung cancer.
Nakamichi S; Seike M; Miyanaga A; Chiba M; Zou F; Takahashi A; Ishikawa A; Kunugi S; Noro R; Kubota K; Gemma A
Oncotarget; 2018 Jun; 9(43):27242-27255. PubMed ID: 29930762
[TBL] [Abstract][Full Text] [Related]
7. The novel FAT4 activator jujuboside A suppresses NSCLC tumorigenesis by activating HIPPO signaling and inhibiting YAP nuclear translocation.
Wang W; Huang Q; Chen Y; Huang Z; Huang Y; Wang Y; Qi X; Liu Z; Lu L
Pharmacol Res; 2021 Aug; 170():105723. PubMed ID: 34116210
[TBL] [Abstract][Full Text] [Related]
8. [Effect and mechanism of silibinin on the inhibition of ALK positive NSCLC cells by sensitizing crizotinib].
Lin CC; Lu CH; Pan YH; Jiao L; Chen HY; Li L; He Y
Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):650-656. PubMed ID: 28926892
[No Abstract] [Full Text] [Related]
9. Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation.
Kim HR; Kim WS; Choi YJ; Choi CM; Rho JK; Lee JC
Mol Oncol; 2013 Dec; 7(6):1093-102. PubMed ID: 23993685
[TBL] [Abstract][Full Text] [Related]
10. FAT4 loss initiates hepatocarcinogenesis through the switching of canonical to noncanonical WNT signaling pathways.
Huang FY; Wong DK; Mak LY; Cheung TT; Zhang SS; Chau HT; Hui RW; Seto WK; Yuen MF
Hepatol Commun; 2023 Dec; 7(12):. PubMed ID: 38055646
[TBL] [Abstract][Full Text] [Related]
11. FAT4 functions as a tumour suppressor in gastric cancer by modulating Wnt/β-catenin signalling.
Cai J; Feng D; Hu L; Chen H; Yang G; Cai Q; Gao C; Wei D
Br J Cancer; 2015 Dec; 113(12):1720-9. PubMed ID: 26633557
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo synergistic efficacy of ceritinib combined with programmed cell death ligand-1 inhibitor in anaplastic lymphoma kinase-rearranged non-small-cell lung cancer.
Du P; Hu T; An Z; Li P; Liu L
Cancer Sci; 2020 Jun; 111(6):1887-1898. PubMed ID: 32227409
[TBL] [Abstract][Full Text] [Related]
13. Autophagy modulates transforming growth factor beta 1 induced epithelial to mesenchymal transition in non-small cell lung cancer cells.
Alizadeh J; Glogowska A; Thliveris J; Kalantari F; Shojaei S; Hombach-Klonisch S; Klonisch T; Ghavami S
Biochim Biophys Acta Mol Cell Res; 2018 May; 1865(5):749-768. PubMed ID: 29481833
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of c-Met and EGFR tyrosine kinase inhibitor resistance through epithelial mesenchymal transition in non-small cell lung cancer.
Rastogi I; Rajanna S; Webb A; Chhabra G; Foster B; Webb B; Puri N
Biochem Biophys Res Commun; 2016 Sep; 477(4):937-944. PubMed ID: 27396618
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of FAT4 suppress metastasis of lung adenocarcinoma through regulating MAPK pathway and associated with immune cells infiltration.
Ning Y; Yang Y; Zheng H; Zhan Y; Zang H; Wen Q; Peng J; Fan S
Cancer Med; 2023 Jan; 12(2):1616-1629. PubMed ID: 35770846
[TBL] [Abstract][Full Text] [Related]
16. d-Borneol enhances cisplatin sensitivity via autophagy dependent EMT signaling and NCOA4-mediated ferritinophagy.
Li J; Yuan J; Li Y; Wang J; Xie Q; Ma R; Wang J; Ren M; Lu D; Xu Z
Phytomedicine; 2022 Nov; 106():154411. PubMed ID: 36030746
[TBL] [Abstract][Full Text] [Related]
17. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM
Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308
[TBL] [Abstract][Full Text] [Related]
18. Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of
Fukuda K; Takeuchi S; Arai S; Katayama R; Nanjo S; Tanimoto A; Nishiyama A; Nakagawa T; Taniguchi H; Suzuki T; Yamada T; Nishihara H; Ninomiya H; Ishikawa Y; Baba S; Takeuchi K; Horiike A; Yanagitani N; Nishio M; Yano S
Cancer Res; 2019 Apr; 79(7):1658-1670. PubMed ID: 30737231
[TBL] [Abstract][Full Text] [Related]
19. EML4-ALK G1202R mutation induces EMT and confers resistance to ceritinib in NSCLC cells via activation of STAT3/Slug signaling.
Shen J; Meng Y; Wang K; Gao M; Du J; Wang J; Li Z; Zuo D; Wu Y
Cell Signal; 2022 Apr; 92():110264. PubMed ID: 35085771
[TBL] [Abstract][Full Text] [Related]
20. The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma.
Wu F; Li J; Jang C; Wang J; Xiong J
Int J Clin Exp Pathol; 2014; 7(10):6653-61. PubMed ID: 25400744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
